Изолированная систолическая артериальная гипертензия: глобальный фактор риска

В.В. Фомин

Кафедра терапии и профболезней медико-профилактического факультета ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, Москва
Обсуждается значение изолированной систолической артериальной гипертензии как фактора риска сердечно-сосудистых осложнений и хронической болезни почек, а также подходы к ее лечению.


1. Комитет экспертов РМОАГ / ВНОК. Диагностика и лечение артериальной гипертензии. Рекомендации РМОАГ/ВНОК. Системные гипертензии. 2010; 3: 5–26.
2. Nawrot T., Den Hond E., Thijs L., Staessen J.A. Isolated systolic hypertension and the risk of vascular disease. Curr. Hypertens. Rep. 2003; 5: 372–379.
3. London G., Marchais S., Guérin A., Métivier F. Arterial hypertension, chronic renal insufficiency and dialysis. Nephrol. Ther. 2007; 3(Suppl. 3): S156–S161.
4. Ochodnicky P., Henning R.H., van Dokkum R.P. et al. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of endorgan damage. Cardiovasc. Pharmacol. 2006; 47 (Suppl. 2): S151–S162.
5. Tsakiris A., Doumas M., Lagatouras D. et al. Microalbuminuria is determined by systolic and pulse pressure over a 12-year period and related to peripheral artery disease in normotensive and hypertensive subjects: the Three Areas Study in Greece (TAS-GR). Angiology. 2006; 57 (3): 313–320.
6. Gerber L.M., Shmukler C., Alderman M.H. Differences in urinary albumin excretion rate between normotensive and hypertensive, white and nonwhite subjects. Arch. Intern. Med. 1992; 152: 373–377.
7. Hanada S., Ando R., Naito S. et al. Assessment and significance of abdominal aortic calcification in chronic kidney disease. Nephrol. Dial. Transplant. 2010; 25(6): 1888–1895.
8. Okuno S., Ishimura E., Kitatani K. et al. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am. J. Kidney Dis. 2007; 49(3): 417–425.
9. McEniery C.M., McDonnell B.J., So A. et al.; Anglo-Cardiff Collaboration Trial Investigators. Aortic calcification is associated with aortic stiffness and isolated systolic hypertension in healthy individuals. Hypertension. 2009; 53(3): 524–531.
10. Cheng L.T., Gao Y.L., Gu Y. et al. Stepwise increase in the prevalence of isolated systolic hypertension with the stages of chronic kidney disease. Nephrol. Dial. Transplant. 2008; 23(12): 3895–3900.
11. Howes L., Reld L., Bendle R. et al. The prevalence of isolated systolic hypertension in patients of 60 years and over attending Australian general practitioners. Blood Press. 1998; 7: 139–143.
12. Antikainen R.L., Jousilahti P., Tuomilehto J. Trends in the prevalence of isolated systolic hypertension in the middle-aged population in 1972–1992. J. Hum. Hypertens. 1999;13: 485–491.
13. Yeh C.J., Pan W.H., Jong Y.S. et al. Incidence and predictors of isolated systolic hypertension and isolated diastolic hypertension in Taiwan. J. Formos. Med. Assoc. 2001; 100: 668–675.
14. Martins D., Nelson K., Pan D. The effect of gender on age-related blood pressure changes and the prevalence of isolated systolic hypertension among older adults: data from NHANES III. J. Gend. Specif. Med. 2001; 4: 10–13.
15. Franklin S.S., Jacobs M.J., Wong N.D. et al. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37: 869–874.
16. Hyman D.J., Pavlik V.N. Characteristics of patients with uncontrolled hypertension in the United States. N. Engl. J. Med. 2001; 345: 479–486.
17. Whyte J.L., Lapuerta P., L©Italien G.J. et al. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988-1994. J. Clin. Hypertens.
(Greenwich). 2001; 3: 211–216.
18. O©Rourke M.F. Isolated systolic hypertension, pulse pressure, and arterial stiffness as risk factors for cardiovascular disease. Curr. Hypertens. Rep. 1999; 1: 204–211.
19. Beltran A., McVeigh G., Morgan D. et al. Arterial compliance abnormalities in isolated systolic hypertension. Am. J. Hypertens. 2001; 14:1007–1011.
20. Lip G.Y., Blann A.D., Beevers D.G. Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic hypertension compared with systolic-diastolic hypertension. J. Hypertens. 1999; 17: 1203–1207.
21. Cirillo M., Stellato D., Laurenzi M. et al Pulse pressure and isolated systolic hypertension: association with microalbuminuria. The GUBBIO Study Collaborative Research Group. Kidney Int. 2000; 58: 1211–1218.
22. Bog-Hansen E., Lindblad U., Ranstam J. et al. Impaired glucose metabolism and obesity in Swedish patients with borderline isolated systolic hypertension: Skaraborg Hypertension and Diabetes Project. Diabetes. Obes. Metab. 2001; 3: 25–31.
23. Denolle T., Gallois H., L©Hostis P. et al. Characteristics of patients with isolated systolic hypertension in relation to body mass index. The PREHSI study. Arch. Mal. Coeur. Vaiss. 2002; 95: 683–636.
24. Kannel W.B. Elevated systolic blood pressure as a cardiovascular risk factor. Am. J. Cardiol. 2000; 85: 251–255.
25. Stampler J., Stampler R., Neaton J. Blood pressure, systolic and diastolic, and cardiovascular risks. Arch. Intern. Med. 1993; 153: 598–615.
26. Broda G. Isolated systolic hypertension is a strong predictor of cardiovascular and all-cause mortality in the middle-aged population: Warsaw Pol-MONICA Follow up Project. J. Clin. Hypertens. (Greenwich). 2000; 2:
27. Qureshi A.I., Suri M.F., Mohammad Y. et al. Isolated and borderline isolated systolic hypertension relative to long-term risk and type of stroke: a 20-year follow-up of the national health and nutrition survey. Stroke 2002; 33: 2781–2788.
28. Pini R., Cavallini M.C., Bencini F. et al. Cardiovascular remodeling is greater in isolated systolic hypertension than in diastolic hypertension in older adults: the Insufficienza Cardiaca negli Anziani Residenti (ICARE) a Dicomano Study. J. Am. Coll. Cardiol. 2002; 40:1283–1289.
29. Hozawa A., Ohkubo T., Nagai K. et al. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: the Ohasama study. Arch. Intern. Med. 2000; 160:3301–3306.
30. Cicconetti P., Morelli S., Ottaviani L. et al. Blunted nocturnal fall in blood pressure and left ventricular mass in elderly individuals with recently diagnosed isolated systolic hypertension. Am. J. Hypertens. 2003; 16 (11 Pt. 1): 900–905.
31. Aronson S., Boisvert D., Lapp W. Isolated systolic hypertension is associated with adverse outcomes from coronary artery bypass grafting surgery. Anesth. Analg. 2002; 94:1079–1084.
32. Vikse B.E., Aasarod K., Bostad L. et al. Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrol. Dial. Transplant. 2003; 18: 517–523.
33. Castellani S., Ungar A., Cantini C. et al. Impaired renal adaptation to stress in the elderly with isolated systolic hypertension. Hypertension 1999; 34: 1106–1111.
34. Mentari E., Rahman M. Blood pressure and progression of chronic kidney disease: importance of systolic, diastolic, or diurnal variation. Curr. Hypertens. Rep. 2004; 6(5): 400–404.
35. Agarwal R., Andersen M.J. Correlates of systolic hypertension in patients with chronic kidney disease. Hypertension. 2005; 46(3): 514–520.
36. Kendrick J., Chonchol M., Gnahn H. et al. Higher systolic blood pressure is associated with progression of carotid intima-media thickness in patients with chronic kidney disease. Kidney Int. 2010; 77(9): 794–800.
37. Alcasar J.M., Rodicio J.L. Ischemic nephropathy: clinical characteristics and treatment. Am. J. Kidney. Dis. 2000; 36: 883–893.
38. Фомин В.В. Ишемическая болезнь почек: клинико-патогенетические особенности, диагностика, лечение. Клин. мед. 2008; 4: 8–14.
39. Staessen J.A., Gasowski J., Wang J.G. et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–872.
40. Alam M.G., Barri Y.M. Systolic blood pressure is the main etiology for poorly controlled hypertension. Am. J. Hypertens. 2003; 16:140–143.
41. Borenstein J., Whyte J.L., Badamgarav E. et al. Physician practice patterns in the treatment of isolated systolic hypertension in a primary care setting. J. Clin. Hypertens. (Greenwich) 2002; 4: 93–100.
42. Moore T.J., Conlin P.R., Ard J., Svetkey L.P. DASH (Dietary Approaches to Stop Hypertension) diet is effective treatment for stage 1 isolated systolic hypertension. Hypertension 2001; 38:155–158.
43. Staessen J.A., Fagard R., Thijs L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–764.
44. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J. Hypertens. 2004; 22: 847–857.
45. SHEP Cooperative Research Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. J.A.M.A. 1991; 265: 3255–3264.
46. Sutton-Tyrrell K., Wildman R., Newman A. et al. Extent of cardiovascular risk reduction associated with treatment of isolated systolic hypertension. Arch. Intern. Med. 2003; 163: 2728–2731.
47. Ramakrishna G., Schechter C.B., Phillips R. Diagnosis and treatment of isolated systolic hypertension in the elderly: results of a survey four years post-SHEP. Am. J. Geriatr. Cardiol. 1997; 6: 21–36.
48. Ferrucci L., Furberg C.D., Penninx B.W. et al. Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile. Circulation 2001; 104: 1923–1926.
49. Perry H.M. Jr., Davis B.R., Price T.R. et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). J.A.M.A. 2000; 284: 465–471.
50. Young J.H., Klag M.J., Muntner P. et al. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J. Am. Soc. Nephrol. 2002; 13: 2776–2782.
51. Zillich A.J., Garg J., Basu S. et al. Thiazide diuretics, potassium and the development of diabetes. A quantative review. Hypertension 2006; 48: 219–224.
52. Sowers J.R., Neutel J.M., Saunders E. et al. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J. Clin. Hypertens. (Greenwich). 2006; 8(7): 470–480.
53. Chrysant S.G., Neutel J.M., Ferdinand K.C.; INCLUSIVE investigators. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. J. Natl. Med.
Assoc. 2009; 101(4): 300–307.
54. Kark M., Karnehed N., Rasmussen F. Blood pressure in young adulthood and later disability pension. A population-based study on 867 672 men from Sweden. Blood Press. 2007;16(6): 362–366.

Об авторах / Для корреспонденции

Фомин В.В. – профессор кафедры терапии и профболезней медико-профилактического факультета, декан факультета довузовского образования ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, д.м.н.
E-mail: fomin_vic@mail.ru

Похожие статьи

Бионика Медиа